Clinical trials: Covid19 Vaccine
COVID-19
Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection.
- Trial name
- DAN-COVID (NCT07279766)
- Testing
- mRNA-1273 (Moderna COVID-19 vaccine)
- Where
- 2 sites in Denmark
- Volunteers
- 41,060 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
Coronavirus
A Study of Intranasal ChAdOx1 nCOV-19
Open label, dose escalation study to investigate: 1. Safety, tolerability and immunogenicity of one or two doses of intranasal ChAdOx1 nCOV-19, in vaccine naïve individuals, with randomisation between one and two dose groups. 2.
- Trial name
- NCT04816019
- Testing
- ChAdOx1 nCov-19
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Perimyocarditis, Covid19
Prevalence of Perimyocarditis After Covid-19 Vaccine
The aim of this study is to determine whether there is a higher prevalence of perimyocarditis after undergoing vaccination for Covid-19.
- Trial name
- NCT04865900
- Testing
- Laboratory Blood Tests, ECG, PCR
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Hillel Yaffe Medical Center
COVID-19
Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19
The objective is to determine the efficacy, immunogenicity and safety of two different strengths (3 µg and 6 µg) of an inactivated COVID 19 Vaccine compared to placebo so that to demonstrate the efficacy and safety in prophylaxis…
- Trial name
- NCT04824391
- Testing
- ERUCOV-VAC 3 µg/0.5 ml Vaccine, ERUCOV-VAC 6 µg/0.5 ml Vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
Influenza, COVID-19 (Coronavirus Disease 2019)
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older.
- Trial name
- NCT06821061
- Testing
- Investigational Influenza Vaccine, Investigational COVID-19 Vaccine, Investigational Influenza and COVID-19 Combination Vaccine
- Where
- 31 sites in United States
- Volunteers
- 2,650 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19 Prevention
An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" Vaccine
Phase I-II open prospective, two-stage, non-randomized study in healthy volunteers.
- Trial name
- NCT04713488
- Testing
- Sputnik Light
- Where
- Russia
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
COVID-19, Solid Tumor
National Project on Vaccines, COVID-19 and Frail Patients
This is a multicentre observational study with the aim of evaluating the antibody and cellular response after vaccination for SARS-CoV-2 with Pfizer-BioNTech or Moderna vaccines in frail subjects with impaired immuno-competence…
- Conditions
- COVID-19, Solid Tumor, Hematologic Diseases, Neurologic Disorder
- Trial name
- VAX4FRAIL (NCT04848493)
- Testing
- COVID-19 vaccines
- Where
- 12 sites in Italy
- Volunteers
- 747 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Covid19
Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above
The aim of the clinical study is to study the safety, reactogenicity and immunogenicity indicators of the EpiVacCorona vaccine, with the involvement of volunteers aged 60 years and above.
- Trial name
- NCT05021016
- Testing
- EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
- Where
- Russia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
Covid19, Vaccine Refusal
COVID-19 Vaccine Hesitancy Among African Americans
Coronavirus disease 2019 (COVID-19) has created a "state of emergency" for African Americans in the US. Recent findings indicate 31% of adults self-reported "wait and see" of the COVID-19 vaccine, of which 16% were African…
- Conditions
- Covid19, Vaccine Refusal, Communication
- Trial name
- NCT04801030
- Testing
- YourCoViDVaxFacts
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Meharry Medical College
COVID-19
Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years.
This is a single center, open-label, parallel controlled, and randomized Phase II clinical trial to evaluate the safety and immunogenicity of two types of Recombinant Novel Corona Virus Vaccine (Adenovirus type 5 vector) in…
- Trial name
- NCT05330871
- Testing
- 1 Nebulized inhalation for booster groups, 2 Nebulized inhalation for booster groups, 3 Nebulized inhalation for booster groups
- Where
- China
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Seventh Medical Center of PLA General Hospital
COVID-19
Safety Study of COVID19 Vaccine on the Market
Popular topic:Multi-center safety observation of recombinant Novel Coronavirus protein vaccine (CHO cells) in a large population Study population:People aged 18 and above
- Trial name
- NCT05890521
- Testing
- Recombinant new coronavirus vaccine (CHO cell)
- Where
- China
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19 Vaccination
Developing and Testing a COVID-19 Vaccination Acceptance Intervention
The COVID-19 pandemic has resulted in significant loss of life and suffering with total case and death counts increasing daily, particularly with the emergence of the delta variant.
- Trial name
- CoVAcS (NCT05027464)
- Testing
- Moving to COVID-19 Vaccine Acceptance Intervention
- Where
- 2 sites in United States
- Volunteers
- 338,718 people
- Sponsor
- VA Office of Research and Development
Coronavirus
A Study of a Candidate COVID-19 Vaccine (COV001)
A phase I/II single-blinded, randomised, multi-centre study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers aged 18-55 years.
- Trial name
- NCT04324606
- Testing
- ChAdOx1 nCoV-19, MenACWY, ChAdOx1 nCoV-19 full boost
- Where
- 6 sites in United Kingdom
- Volunteers
- 1,077 people, healthy volunteers welcome
- Sponsor
- University of Oxford
COVID-19
A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil
The present test-negative design study aims to estimate the real-world effectiveness of Pfizer-BioNTech BNT162b2 mRNA vaccine on symptomatic SARS-CoV-2 infection and its consequences among children aged 5 to 11 years in the city…
- Trial name
- NCT05403307
- Testing
- Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine, CoronaVac COVID-19 vaccine
- Where
- 5 sites in Brazil
- Volunteers
- 757 people
- Sponsor
- Hospital Moinhos de Vento
COVID-19
COVID-19 Vaccine Hesitancy Counseling Intervention for Pharmacists
The goal of this clinical trial is to test if virtual facilitation (e.g., video coaching) increases rural pharmacists' ability to implement COVID-19 vaccine hesitancy counseling when compared to a "standard" implementation…
- Trial name
- NCT05926544
- Testing
- Standard implementation webinar and online training, Virtual facilitation
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of North Carolina, Chapel Hill
COVID-19, Influenza
A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
This is a randomized, observer-blinded, Phase 2 study evaluating the safety and immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARSCoV2) recombinant spike (rS) (SARS-CoV-2 rS) nanoparticle and quadrivalent…
- Trial name
- COVID-19 (NCT05519839)
- Testing
- qNIV Vaccine with Matrix-M Adjuvant, Influenza Vaccine, CIC Vaccine with Matrix-M Adjuvant
- Where
- 35 sites in Australia, New Zealand
- Volunteers
- 1,579 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19 Vaccine
A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19
This primary objective of the study is to measure the anti-SARS-CoV-2 neutralizing antibody titers in adult participants in order to demonstrate the immunogenicity and safety of heterologous third-boost with MVC-COV1901, in terms…
- Trial name
- NCT05097053
- Testing
- MVC-COV1901(3 Months), MVC-COV1901(6 Months)
- Where
- Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Taoyuan General Hospital
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
A Clinical Trial to Study the COVAC-1 Booster Dose in Generally Healthy Adults
VIDO has developed a vaccine called COVAC-1. The COVAC-1 study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1.
- Trial name
- NCT05693272
- Testing
- COVAC-1
- Where
- 4 sites in Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
Vaccine Response Impaired, Immune Suppression
Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients
This study will be a randomized, double-blind, placebo-controlled trial of a third dose of Moderna vaccine versus placebo. Participants will be those that have received two doses of mRNA-1273 COVID vaccine (Moderna) at 0 and 1…
- Conditions
- Vaccine Response Impaired, Immune Suppression, Covid19
- Trial name
- NCT04885907
- Testing
- mRNA-1273 vaccine
- Where
- 2 sites in Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
X-linked Agammaglobulinemia, XLA
COVID-19 Vaccine Responses in PIDD Subjects
The goal of our study is to assess the cellular immune responses of participants with antibody deficiency disease before and after immunization with SARS-CoV-2 mRNA vaccines.
- Conditions
- X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID
- Trial name
- NCT05321407
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.